Stocktoria
BIO-TECHNE Corp TECH
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1989-02-09
BIO-TECHNE Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% |
| Operating margin | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% |
| Net margin | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% |
| FCF margin | 21.0% | 20.4% | 19.0% | 25.4% | 33.1% |
| Return on assets | 2.9% | 6.2% | 10.8% | 11.9% | 6.2% |
| Return on equity | 3.8% | 8.1% | 14.5% | 16.0% | 8.9% |
| Current ratio | 3.46 | 3.87 | 4.84 | 3.44 | 3.35 |
| Revenue growth | 5.2% | 2.0% | 2.8% | 18.7% | 26.0% |
Source: SEC EDGAR filings · CIK 0000842023 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.